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South Korea than Taiwan. The health care resource burden of MGC is considerable 
in both countries, as hospitalisation is common, particularly in Taiwan.
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Objectives: To compare the allocation of hospital costs per treatment cycle (HCTC) 
associated with first-line chemotherapy for advanced non-squamous non-small cell 
lung cancer (AdvNS-NSCLC) in Chinese patients. MetHODs: Patients receiving first-
line chemotherapy for AdvNS-NSCLC from 2010 to 2012 were retrospectively iden-
tified from two tertiary care hospitals in Hunan province, China. Propensity score 
matched treatment groups for pemetrexed-platinum versus other doublets were 
created for head-to-headcomparisons on the allocation of HCTC using Wilcoxon 
signed rank test. Multiple linear regression analyses were performed to assess the 
impact of the studied doublets on log10 scale of HCTC for supportive care, including 
non-chemotherapy drugs and non-drug care, by comparing vinorelbine-platinum in 
patients stratified by tumor response and hematological adverse events. Results: 
447 patients were included to create propensity score matched treatment groups 
for pemetrexed-platinum versus docetaxel-platinum (61 pairs), paclitaxel-platinum 
(39 pairs), gemcitabine-platinum (93 pairs), and vinorelbine-platinum (73 pairs), 
respectively. Total HCTC was significantly greater with pemetrexed-platinum than 
other platinum doublets (median difference ranged from RMB 1,692 to RMB 7,400, p 
≤ 0.001, 1 RMB = 0.16 US$). Pemetrexed-platinum was associated with significantly 
higher HCTC for non-platinum cytotoxic agent (median difference ranged from RMB 
4,636 to RMB 7,332, p < 0.001) but significantly lower HCTC for non-chemotherapy 
drugs (median difference ranged from –RMB 1,551 to –RMB 2,502, p ranged from < 
0.001 to 0.012). There were no significant differences for platinum drugs or non-drug 
care. Pemetrexed-platinum was ranked lowest for the log10 scale of HCTC for sup-
portive care in all patients (coefficient -0.174, p= 0.015) and also in patients with any 
hematological adverse events (coefficient -0.199, p= 0.013), neutropenia (coefficient 
-0.426, p= 0.021) or leukopenia (coefficient -0.406, p= 0.001). cOnclusiOns: Among 
first-line Chinese AdvNS-NSCLC patients, non-platinum cytotoxic drug HCTC was 
significantly higher with pemetrexed-platinum. This was partially offset by sig-
nificantly lower HCTC for non-chemotherapy drugs than other platinum-based 
doublets.
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Objectives: The primary objective of this study was to describe the economic bur-
den on solid tumor and lymphoma patients who received inpatient management 
of chemotherapy-induced febrile neutropenia (FN). The secondary objective was to 
identify any clinical factors associated with the economic burden. MetHODs: This 
was a single-center observational study conducted at the largest cancer center in 
Singapore. All of the adult cancer cases diagnosed with solid tumors or lymphoma 
and hospitalized due to FN from 2009 to 2012 were studied. The primary outcomes 
were the total hospital cost (uncensored) and the out-of-pocket cost (censored by 
government subsidy) per FN episode. Descriptive analysis was utilized to describe 
the cost within subgroups. Univariate analysis and multiple linear regression were 
conducted to identify the factors associated with higher FN costs. Results: Four 
hundred and thirteen hospitalizations with FN were documented in 367 adult cancer 
patients. The mean total hospital cost was US$5,244 (95% CI: US$4,758-5,730) and 
the mean out-of-pocket cost was US$2,847 (95% CI: US$2,516-3,178), per FN episode 
for all of the hospitalizations. Lymphoma patients had a significantly higher total 
hospital cost (p < 0.001) and out-of-pocket cost (p < 0.001) than those with other 
types of cancer. The clinical factors associated with a higher total hospital cost were 
longer length of stay, longer time to recover the absolute neutrophil count, severe 
sepsis, and lymphoma as underlying cancer. The out-of-pocket cost was positively 
associated with longer length of stay, severe sepsis, lymphoma as underlying cancer, 
the therapeutic use of granulocyte colony-stimulating factor (GCSF), the private 
ward class, and younger patients. cOnclusiOns: The economic burden of FN man-
agement in lymphoma cases was substantial compared with other solid tumors. 
Factors associated with a higher FN management cost may be useful for developing 
appropriate strategies to reduce the economic burden of FN for cancer patients.
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Objectives: The problem of treatment of breast cancer is one of the most impor-
tant and most difficult in modern oncology. Breast cancer is currently tops the list 
of cancers in women. Domestic herbal preparation “Arglabin” was synthesized by 
Scientific-Production Center “Phytochemistry” (Kazakhstan) as a drug with anti-
cancer and immunomodulatory activity for the complex therapy of malignant 
tumors. Purpose of the study was to evaluate the clinical and cost-effectiveness of 
the original drug “Arglabin” in patients with disseminated breast cancer in clinical 
practice. MetHODs: We compared the cost-effectiveness of standard scheme of 
treatment of breast cancer with CMF (cyclophosphamide + methotrexate + fluo-
rouracil) vs CMF with Arglabin as additional agent to standard treatment through 
performing a cost-effectiveness analysis (CEA) and cost of illness (COI). Effectiveness 
terms included those related to CC, risk factor and Chinese population. The search 
was not restricted in terms of time span or language. The abstracts and selected 
manuscripts were assessed (content and quality) by two independent review-
ers. Results: 1,737 citations were identified and screened and approximately 100 
publications were included for data synthesis. All studies were conducted at regional 
level, but not country level. Main risk factors reported as statistically associated to 
CC were: 1) socio-demographics: age and education level; 2) life-style behaviour: 
dietary consumption, smoking status and personal hygiene; 3) sexual behaviour: 
number of partners (self and partner), number of marriages, age at sexual debut, 
age at first marriage; 4) gestational factors: age at first pregnancy, total number 
of pregnancies, contraceptive method; 5) screening and disease history: cervical 
screening, gynaecological diseases, family disease history and other diseases. 
Large heterogeneity exists between the studies in the definition used for these risk 
factors. cOnclusiOns: This systematic review provided an up-to-date insight of 
risk factors for developing CC in China. Due to heterogeneity, further evaluation is 
needed to allow combining risk factors. A statistical analysis is warranted to assess 
the contribution of each risk factor to the overall risk.
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Objectives: Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved 
globally for the first- and second-line treatment of metastatic renal cell carcinoma 
(mRCC). The purpose of this study was to assess the budget impact of using suni-
tinib as first-line therapy in urban Chinese patients from a Chinese payer perspec-
tive. MetHODs: A user friendly budget impact model was constructed to compare 
the overall budget impact with and without sunitinib incorporated in the formulary. 
An up to 3-year time horizon with 6 weekly cycle treatment was used to estimate 
the overall budget impact for mRCC patients from a third-party payer perspective. 
The analysis was conducted with the following 3 comparators based on China treat-
ment pattern included in the model: sunitinib, INF-a, and sorafenib. Epidemiology 
data, drug costs, adverse events information, and health care resources associated 
with the treatments and adverse events (AE) were obtained from the literature. 
Costs were expressed in 2013 prices. The analysis used Shanghai population as 
the base case. Budgetary impact for other large cities in China can be estimated by 
substituting the various city populations. Results: In Shanghai, patients eligible 
for first line treatment were estimated at 892. If Sunitinib is added into the formulary 
with the current retail price, the estimated net budgetary impact for 3 years total 
is RMB82,369,048.84. This is equivalent to about RMB0.10 budget impact per mem-
ber per month (PMPM) with significantly improved clinical efficacy. A sensitivity 
analysis indicated that the increased budget impact is a direct result of patients on 
Sunitinib treatment experienced superior Mean progression free survival time over 
competitors. cOnclusiOns: The results suggested that the addition of Sunitinib in 
the formulary as first-line therapy for mRCC in urban China would improve patient 
clinical outcomes with moderate impact on the overall payer budget.
PCN7
HealtH Care resourCe use amoNg advaNCed gastriC CaNCer PatieNts 
iN taiwaN aNd soutH Korea
Rajan N1, Cuyun Carter G2, Kaltenboeck A3, Ivanova J3, Liepa AM2, San Roman A4, Koh M3, 
Ballal S5, Birnbaum H4, Cheng R6, Chen JS7, Bang YJ8
1Eli Lilly and Company, West Ryde, Australia, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3Analysis Group, Inc., New York, NY, USA, 4Analysis Group, Inc., Boston, MA, USA, 5ImClone 
Systems, Inc., New York, NY, USA, 6Eli Lilly and Company, Taipei, Taiwan, 7Linkou Chang Gung 
Memorial Hospital, Chang Gung University College of Medicine, Tao-Yuan, Taiwan, 8Seoul 
National University Hospital, Seoul, South Korea
Objectives: To assess health care resource use associated with the treatment 
of metastatic and/or locally recurrent, unresectable gastric cancer (MGC), includ-
ing cancer of the stomach and gastro-oesophageal junction, in Taiwan and South 
Korea. MetHODs: Physicians, randomly selected from a panel of oncologists and 
study referrals, supplied de-identified information via an online chart abstraction 
instrument, for ≤ 10 randomly selected patients with MGC. Patients were required 
to have received platinum/fluoropyrimidine first-line therapy, followed by second-
line therapy or best supportive care (BSC) only. Data were analysed using sum-
mary statistics. Results: Data were collected (2/2013–7/2013) for 122 patients from 
37 physicians in Taiwan, and for 198 patients from 30 physicians in South Korea. 
Key demographics in Taiwan and South Korea, respectively, included: men (62.3%; 
73.7%); mean age (59.8 years; 61.3 years). Following first-line treatment, patients 
in Taiwan and South Korea, respectively, received: second line (64.8%; 80.3%); BSC 
alone (35.2%; 19.7%); third line (13.1%; 23.2%). Inpatient hospitalisation rates (≥ 1 
stay) in Taiwan and South Korea, respectively, were: overall, i.e. including periods 
of no line of treatment (82.8%, [101/122]; 48.5%, [96/198]); first line (63.1%, [77/122]; 
35.9%, [71/198]); second line (53.2%, [42/79]; 30.2%, [48/159]); BSC alone (39.5%, [17/43]; 
33.3%, [13/39]); third line (68.8%, [11/16]; 23.9%, [11/46]). In both countries, inpatient 
hospitalisations were of similar mean length (Taiwan, 8.6 days [SD 10.0]; South 
Korea, 8.7 days [SD 9.8]). Most common reasons for inpatient hospitalisation were 
chemotherapy infusions (Taiwan, 59.8%; South Korea, 67.9%) and disease symptom 
management (Taiwan, 30.4%; South Korea, 20.3%). Overall, antiemetics and anal-
gesics were the most common supportive-care agents; endoscopy was the most 
common procedure. cOnclusiOns: In both countries, > 60% of patients with MGC 
received second-line treatment; post-first-line treatments were more common in 
